drugset / Trial / NCT07532902
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Timeline
- Start
- 2026-04-07
- Primary completion
- 2029-04
- Completion
- 2029-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986504 | Unknown | — | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Nivolumab | Monoclonal antibody | 360 mg | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |